Keyword search (4,164 papers available)

"He M" Authored Publications:

Title Authors PubMed ID
1 Segregation of competing voices by their fundamental frequency relies on low-frequency regions Calinescu C; Deroche M; 41817225
PSYCHOLOGY
2 Psychophysical evidence of the harmonic cancellation process and its relationship to pitch sensitivity and voice segregation Deroche M; Montagnese J; Khoury K; Iuliano R; Alemi R; 41263633
PSYCHOLOGY
3 Reduced Eye Blinking During Sentence Listening Reflects Increased Cognitive Load in Challenging Auditory Conditions Coupal P; Zhang Y; Deroche M; 40910460
PSYCHOLOGY
4 Technical recommendations for analyzing oxylipins by liquid chromatography-mass spectrometry Schebb NH; Kampschulte N; Hagn G; Plitzko K; Meckelmann SW; Ghosh S; Joshi R; Kuligowski J; Vuckovic D; Botana MT; Sánchez-Illana Á; Zandkarimi F; Das A; Yang J; Schmidt L; Checa A; Roche HM; Armando AM; Edin ML; Lih FB; Aristizabal-Henao JJ; Miyamoto S; Giuffrida F; Moussaieff A; Domingues R; Rothe M; Hinz C; Das US; Rund KM; Taha AY; Hofstetter RK; Werner M; Werz O; Kahnt AS; Bertrand-Michel J; Le Faouder P; Gurke R; Thomas D; Torta F; Milic I; Dias IHK; Spickett CM; Biagini D; Lomonaco T; Idborg H; Liu J 40392938
CHEMBIOCHEM
5 Pupillometry reveals effects of pitch manipulation within and across words on listening effort and short-term memory Zhang Y; Sares A; Delage A; Lehmann A; Deroche M; 39349635
CONCORDIA
6 Differences Between French and English in the Use of Suprasegmental Cues for the Short-Term Recall of Word Lists Lew EC; Sares A; Gilbert AC; Zhang Y; Lehmann A; Deroche M; 39320319
PSYCHOLOGY
7 The role of language in ethnic identity measurement: a multitrait-multimethod approach to construct validation Laroche M; Pons F; Richard MO; 19702108
JMSB
8 OFC neurons do not represent the negative value of a conditioned inhibitor Esber GR; Usypchuk A; Saini S; Deroche M; Iordanova MD; Schoenbaum G; 38042330
CONCORDIA
9 Audiovisual integration in children with cochlear implants revealed through EEG and fNIRS Alemi R; Wolfe J; Neumann S; Manning J; Towler W; Koirala N; Gracco VL; Deroche M; 37989460
PSYCHOLOGY
10 Motor Processing in Children With Cochlear Implants as Assessed by Functional Near-Infrared Spectroscopy Alemi R; Wolfe J; Neumann S; Manning J; Hanna L; Towler W; Wilson C; Bien A; Miller S; Schafer E; Gemignani J; Koirala N; Gracco VL; Deroche M; 37977135
PSYCHOLOGY
11 Factors Associated with Speech-Recognition Performance in School-Aged Children with Cochlear Implants and Early Auditory-Verbal Intervention Wolfe J; Deroche M; Neumann S; Hanna L; Towler W; Wilson C; Bien AG; Miller S; Schafer EC; Gracco V; 34847584
PSYCHOLOGY
12 Flame-Retardant and Polysulfide-Suppressed Ether-Based Electrolytes for High-Temperature Li-S Batteries He M; Li X; Holmes NG; Li R; Wang J; Yin G; Zuo P; Sun X; 34370436
ENCS
13 A Cross-Sectional Study on the Impact of Arterial Stiffness on the Corpus Callosum, a Key White Matter Tract Implicated in Alzheimer's Disease Badji A; de la Colina AN; Boshkovski T; Sabra D; Karakuzu A; Robitaille-Grou MC; Gros C; Joubert S; Bherer L; Lamarre-Cliche M; Stikov N; Gauthier CJ; Cohen-Adad J; Girouard H; 32741837
PERFORM
14 Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J, SPIN Investigators, Baron M, Furst DE, Gottesman K, Malcarne V, Mayes MD, Mouthon L, Nielson WR, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson SR, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna TSR, Schouffoer AA, Suarez-Almazor ME, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein EJ, Berthier S, Biss 32419703
PSYCHOLOGY
15 Association Between Paraspinal Muscle Morphology, Clinical Symptoms, and Functional Status in Patients With Degenerative Cervical Myelopathy. Fortin M, Dobrescu O, Courtemanche M, Sparrey CJ, Santaguida C, Fehlings MG, Weber MH 28207658
PERFORM
16 Enzymatic assay for GHB determination in forensic matrices. Grenier V, Huppé G, Lamarche M, Mireault P 22722059
MASSSPEC
17 Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Laroc 27118291
HKAP
18 Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell 28449828
HKAP
19 Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, 29731013
NA

 

Title:Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients.
Authors:Fortuné CGietzen AGuillot GLewis NNielsen KRichard MSauvé MWelling JSPIN InvestigatorsBaron MFurst DEGottesman KMalcarne VMayes MDMouthon LNielson WRRiggs RWigley FAssassi SBoutron IElls Cvan den Ende CFligelstone KFrech TGodard DHarel DHinchcliff MHudson MJohnson SRLarche MLeite CNguyen CPope JPortales ARannou FReyna TSRSchouffoer AASuarez-Almazor MEAgard CAlbert AAndré MArsenault GBenzidia IBernstein EJBerthier SBiss
Link:https://www.ncbi.nlm.nih.gov/pubmed/32419703?dopt=Abstract
DOI:10.1016/j.jpsychores.2020.110132
Publication:Journal of psychosomatic research
Keywords:AnxietyCOVID-19CoronavirusMental healthRCTSclerodermaSystemic sclerosisTrial
PMID:32419703 Category:J Psychosom Res Date Added:2020-05-19
Dept Affiliation: PSYCHOLOGY
1 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Department of Psychology, McGill University, Montreal, Quebec, Canada; Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada; Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada. Electronic address: brett.thombs@mcgill.ca.
2 Department of Clinical Psychology, Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands.
3 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
4 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
5 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
6 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Psychology, McGill University, Montreal, Quebec, Canada.
7 Department of Applied Human Sciences, Concordia University, Montreal, Quebec, Canada.
8 Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
9 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.
10 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada.
11 Department of Applied Human Sciences, Concordia University, Montreal, Quebec, Canada; Department of Oncology, Cumming School of Medicine, Calgary, Canada; Department of Psychosocial Resources, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada.
12 Department of Psychology, Université du Québec à Montréal, Montreal, Quebec, Canada.
13 Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
14 Scleroderma Foundation Michigan Chapter, Southfield, MI, USA.
15 Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
16 Northwestern Scleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
17 Ottawa Scleroderma Support Group, Ottawa, Ontario, Canada.
18 Scleroderma Foundation, Danvers, Massachusetts, USA.
19 Sclérodermie Québec, Longueuil, Quebec, Canada.
20 Toronto, Ontario, Canada.
21 Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
22 Past-president of Scleroderma Canada, Halifax, Nova Scotia, Canada.
23 Scleroderma Society of Ontario and Scleroderma Canada, Hamilton, Ontario, Canada.
24 NVLE Du

Description:

Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients.

J Psychosom Res. 2020 May 14;:110132

Authors: Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J, SPIN Investigators, Baron M, Furst DE, Gottesman K, Malcarne V, Mayes MD, Mouthon L, Nielson WR, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson SR, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna TSR, Schouffoer AA, Suarez-Almazor ME, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein EJ, Berthier S, Bissonnette L, Boire G, Bruns A, Carreira P, Casadevall M, Chaigne B, Chung L, Cohen P, Correia C, Dagenais P, Denton C, Domsic R, Dubois S, Dunne JV, Dunogue B, Fare R, Farge-Bancel D, Fortin PR, Gill A, Gordon J, Granel-Rey B, Gyger G, Hachulla E, Hatron PY, Herrick AL, Hij A, Hoa S, Ikic A, Jones N, Fernandes AJB, Kafaja S, Khalidi N, Lambert M, Launay D, Liang P, Maillard H, Maltez N, Manning J, Marie I, Martin M, Martin T, Masetto A, Maurier F, Mekinian A, Melchor S, Nikpour M, Olagne L, Poindron V, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Smets P, Smith D, Sobanski V, Spiera R, Steen V, Stevens W, Sutton E, Terrier B, Thorne C, Varga J, Wilcox P, Ayala MC, Ostbo N, Thombs BD, Kwakkenbos L, Carrier ME, Bourgeault A, Tao L, Harb S, Gagarine M, Rice D, Bustamante L, Ellis K, Duchek D, Wu Y, Bhandari PM, Neupane D, Carboni-Jiménez A, Henry RS, Krishnan A, Sun Y, Levis B, He C, Turner KA, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett SJ, Dyas L, Patten S, Varga J, Scleroderma Patient-centered Intervention Network (SPIN), COVID-19 Patient Advisory Team

Abstract

Objective: Contagious disease outbreaks and related restrictions can lead to negative psychological outcomes, particularly in vulnerable populations at risk due to pre-existing medical conditions. No randomised controlled trials (RCTs) have tested interventions to reduce mental health consequences of contagious disease outbreaks. The primary objective of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate the effect of a videoconference-based program on symptoms of anxiety. Secondary objectives include evaluating effects on symptoms of depression, stress, loneliness, boredom, physical activity, and social interaction.

Methods: The SPIN-CHAT Trial is a pragmatic RCT that will be conducted using the SPIN-COVID-19 Cohort, a sub-cohort of the SPIN Cohort. Eligible participants will be SPIN-COVID-19 Cohort participants without a positive COVID-19 test, with at least mild anxiety (PROMIS Anxiety 4a v1.0 T-score?=?55), not working from home, and not receiving current counselling or psychotherapy. We will randomly assign 162 participants to intervention groups of 7 to 10 participants each or waitlist control. We will use a partially nested RCT design to reflect dependence between individuals in training groups but not in the waitlist control. The SPIN-CHAT Program includes activity engagement, education on strategies to support mental health, and mutual participant support. Intervention participants will receive the 4-week (3 sessions per week) SPIN-CHAT Program via videoconference. The primary outcome is PROMIS Anxiety 4a score immediately post-intervention.

Ethics and dissemination: The SPIN-CHAT Trial will test whether a brief videoconference-based intervention will improve mental health




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University